Summary & Overview
HCPCS Level II J3430: Injection, Phytonadione (Vitamin K), per 1 mg
HCPCS Level II code J3430 designates the injectable medication phytonadione (vitamin K), billed per 1 mg unit. Vitamin K injections are used for reversal of anticoagulation, treatment of deficiency states, and management of certain bleeding disorders, making this code clinically important across inpatient and outpatient settings nationwide. Payers commonly encounter J3430 in hospital, emergency, and ambulatory care claims where rapid correction of coagulopathy or prophylaxis is required.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for J3430, typical sites of service, and the common billing considerations tied to an injectable, weight- or dose-based drug code. The publication also outlines expected benchmarking topics such as unit pricing, utilization patterns by site of care, and payer policy considerations for injectable vitamin K.
This summary provides a national view without state-specific policy references. Data not available in the input is identified where applicable. The content is intended to support billing professionals, revenue cycle staff, and policy analysts in understanding the role of HCPCS Level II code J3430 in claims and clinical workflows.
Billing Code Overview
HCPCS Level II code J3430 represents an injection of phytonadione (vitamin K), per 1 mg. This code covers administration of vitamin K provided as a medication unit measured in milligrams.
Service type: Medication administration / injectable drug
Typical site of service: Outpatient clinic, hospital inpatient, emergency department, or ambulatory surgical center, depending on clinical need and ordering provider. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves a neonate, infant, or adult on long-term warfarin therapy who requires parenteral vitamin K (phytonadione) for reversal of excessive anticoagulation or treatment of vitamin K deficiency. Common presentations include elevated INR with minor or no bleeding, active bleeding with supratherapeutic INR, or newborns who did not receive prophylactic oral vitamin K at birth and present with bleeding or high-risk laboratory findings.
Workflow: On identification of an elevated INR or clinical bleeding, the provider documents the indication and orders J3430 specifying the dose in mg. Nursing verifies allergy history, prepares the appropriate concentration of phytonadione, and administers via slow IV push or deep subcutaneous injection per institutional protocol. For anticoagulation reversal, concurrent monitoring includes repeat INR testing and observation for bleeding. For newborn prophylaxis or treatment, administration may occur in the newborn nursery, neonatal ICU, or outpatient clinic, with documentation of informed consent when required and the route and dose recorded in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used — standard reporting | Rarely appended; indicates no special circumstance when required by payer |